The efficacy and safety profile of anlotinib plus docetaxel as second-line treatment in advanced non-small cell lung cancer.

被引：0
|
作者：
Xu, Zhiqiao [1 ]
Zhang, Yan [1 ]
机构：
[1] Kaifeng Cent Hosp, Kaifeng, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e21068
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21068
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer
    J. Feliu
    G. Martín
    J. Castro
    A. Sundlov
    A. Rodriguez-Jaráiz
    E. Casado
    M. Lomas
    C. Madroñal
    A. Galán
    C. Belda
    M. Gonzalez-Barón
    [J]. Cancer Chemotherapy and Pharmacology, 2006, 58 : 527 - 531
  • [2] Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer
    Feliu, J.
    Martin, G.
    Castro, J.
    Sundlov, A.
    Rodriguez-Jaraiz, A.
    Casado, E.
    Lomas, M.
    Madronal, C.
    Galan, A.
    Belda, C.
    Gonzalez-Baron, M.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (04) : 527 - 531
  • [3] Advanced non-small cell lung cancer. Maintenance and second-line treatment
    Schuette, W.
    Nagel, S.
    Haak, G.
    Steinert, M.
    [J]. PNEUMOLOGE, 2012, 9 (01): : 43 - 48
  • [4] Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer
    Gao, Guanghui
    Zhao, Jun
    Ren, Shengxiang
    Wang, Yina
    Chen, Gongyan
    Chen, Jianhua
    Gu, Kangsheng
    Guo, Renhua
    Pan, Yueyin
    Wang, Quanren
    Li, Weixia
    Yang, Xinfeng
    Zhou, Caicun
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (08)
  • [5] Docetaxel as Second-line Monotherapy for Advanced Non-small Cell Lung Cancer
    Kang, Hyun Mo
    Lee, Jeong Eun
    Jang, Pil Soon
    Lee, Yun Sun
    Kwon, Sun Jung
    An, Jin Young
    Jung, Sung Soo
    Kim, Ju Ock
    Kim, Sun Young
    [J]. TUBERCULOSIS AND RESPIRATORY DISEASES, 2005, 58 (05) : 465 - 472
  • [6] Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer?
    Cortinovis, Diego
    Bidoli, Paolo
    Cullura, Daniela
    Lorusso, Vito
    Ardizzoia, Antonio
    Amoroso, Vito
    Bandera, Mauro
    Aitini, Enrico
    Fusi, Alberto
    Zilembo, Nicoletta
    Radula, Daniela
    Bajetta, Emilio
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (04) : 405 - 411
  • [7] Weekly docetaxel as a second-line treatment for advanced non-small cell lung cancer (NSCLC).
    García, R
    Pérez, P
    Alfonso, R
    Pérez-Manga, G
    Díaz-Rubio, E
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 116 - 116
  • [8] Efficacy and safety analysis of anlotinib combined with immunotherapy as second-line therapy for advanced non-small cell lung cancer (NSCLC)
    Shi, Q.
    Xie, Q.
    Lin, H.
    He, Y.
    Zheng, X.
    Zhou, Z.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1568 - S1568
  • [9] Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer
    Pesek, M
    Holá, V
    [J]. LUNG CANCER: CURRENT TOPICS, 2001, : 155 - 160
  • [10] Updated results from a phase I/II study of anlotinib plus docetaxel vs docetaxel as second-line treatment of advanced non-small cell lung cancer (NSCLC)
    Fang, Y.
    Pan, H.
    Shou, J.
    Hong, W.
    Chen, J.
    Wang, Y.
    Guo, Q.
    Lu, L.
    Rao, C.
    Yang, X.
    Zhu, D.
    Lan, F.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1021 - S1021
12345